Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DRT-102
- Development stage
- Preclinical
- Lead developer
- Darnatein
- Modality
- Recombinant Proteins and Enzymes
01
Overview
DRT-102 is a biological drug candidate classified as a bone morphogenetic protein 1 (BMP1) agonist. It was initially developed by Darnatein Co. Ltd. and is currently in the preclinical stage of development. The primary mechanism of action involves agonism of BMP1, which plays a role in bone formation and repair processes. The main therapeutic area under investigation for DRT-102 is spinal injuries, with potential applications in other diseases related to tissue regeneration or repair[1]. There are indications that an exploratory human clinical trial involving four patients (excluding two dropouts) has been conducted[2].
02
Targets
BMP1 (Bone morphogenetic protein 1)
Beyond the preview
Go deeper on DRT-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DRT-102.